CTLA4 and neoplasm: Kim and co‐workers developed neuropilin‐1 (Nrp1) decorated PLGA/lipid hybrid nanoparticles for targeted delivery of anti‐CTLA‐4 mAbs to Nrp1 receptor expressing intratumoral Tregs.[98] The engineered nanoformulation elevated the frequency of tumor infiltrating CD8+ T cells by blocking Tregs‐mediated immunosuppression, thereby enhancing tumor regression.